COMMENT|ONLINE FIRST
Published:October 28, 2019DOI:https://doi.org/10.1016/S2215-0366(19)30375-X
There is a pressing need to develop new medications for the treatment of psychiatric disorders. There is growing public interest in the use of cannabis and its principal constituent cannabinoids, Δ9-tetrahydrocannabinol (THC) and cannabidiol, for a plethora of conditions, including psychiatric disorders. 1In parallel, there is considerable commercial interest in touting these products as treatments for various disorders. As a result, health practitioners need to be well informed about this topic. However, although the potential therapeutic use of cannabinoids receives substantial coverage in the media, more scientific information is needed about this topic that is based on careful systematic reviews or meta-analyses. Although there have been a few reviews of existing evidence have been published, 2, 3, 4, 5, 6 none has considered all the available evidence, the potential differential effects of different cannabinoids, and the safety of these compounds in mental disorders. The review and meta-analysis in The Lancet Psychiatry by Nicola Black and colleagues 7 therefore addresses some of these limitations.
To read this article in full you will need to make a payment
Access any 5 articles from the Lancet Family of journals
Subscribe to The Lancet Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- 1.
The emerging public discourse on state legalization of marijuana for recreational use in the US: analysis of news media coverage, 2010–2014.
Prev Med. 2016; 90: 114-120
- 2.
Marijuana legalization: impact on physicians and public health.
Annu Rev Med. 2016; 67: 453-466
- 3.
A systematic review of the evidence for medical marijuana in psychiatric indications.
J Clin Psychiatry. 2016; 77: 1050-1064
- 4.
Medical marijuana: what physicians need to know.
J Clin Psychiatry. 2019; 8018ac12537
- 5.
Cannabinoids for medical use: a systematic review and meta-analysis.
JAMA. 2015; 313: 2456-2473
- 6.
Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review.
JAMA. 2015; 313: 2474-2483
- 7.
Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis.
Lancet Psychiatry. 2019; (published online Oct 28)
- 8.
Medical marijuana: is the cart before the horse?.
JAMA. 2015; 313: 2431-2432
Article Info
Publication History
Published: October 28, 2019
Identification
Copyright
© 2019 Elsevier Ltd. All rights reserved.
